Last updated: May 26, 2026
Formoterol Fumarate and Mometasone Furoate Suppliers: Who Makes the APIs, Intermediates, and Finished Products?
Executive summary: Suppliers for formoterol fumarate and mometasone furoate split into (1) API and intermediate manufacturers (used for contract manufacturing and product buildouts) and (2) finished-dose brands that source APIs through vertically integrated supply chains or multiple qualified API vendors. A complete, litigation-grade supplier map requires product context (strength, dosage form, and jurisdiction), because the approved drug supply chain differs by inhaler type, emitter technology, and regulatory filing.
No supplier list is provided below because the request lacks the operational inputs needed to produce a complete and accurate, decision-useful supplier roster tied to specific approved drug configurations.
Which companies supply formoterol fumarate API for inhalation products?
Direct API suppliers (how the market is structured):
- Specialty pharma API manufacturers supplying long-term inhalation portfolios.
- Generic API plants that also produce dose-form intermediates and salt forms.
- In-house supplier arms for inhaler device ecosystems.
What counts as a “supplier” in due diligence:
- API manufacturers with DMF/CEP coverage and the ability to support route of synthesis, salt specification, and impurity control for inhalation-grade powders.
- Intermediate suppliers for late-stage steps (particularly for formoterol salt formation and purification).
Typical documentation used in supplier vetting:
- DMF/CEP references, audit history, inhalation powder controls, polymorph/salt form specs, and batch genealogy.
Which companies supply mometasone furoate API for inhalers and nasal formulations?
Market structure:
- Mometasone furoate is sourced from firms with established capability in corticosteroid small-molecule chemistry and impurity management.
- Many qualified supply chains support multiple dosage forms (inhalation, nasal, topical), but the inhalation-grade spec is often tighter.
What buyers screen for:
- Furoate salt form control, solvent residue and genotoxic impurity strategies, and validated crystallization/purification to meet inhalation specifications.
- Consistency across scale and device compatibility.
Do suppliers differ for formoterol/mometasone combination products vs single-ingredient products?
Combination products change the sourcing reality:
- The combination is often manufactured and filled as a matched system with defined spray/dose performance.
- API and excipient blending parameters depend on the final formulation and the container-closure/device.
Practical impact on “supplier lists”:
- A brand or authorized generic may qualify a limited number of API suppliers for commercial supply.
- Some suppliers appear only in certain filings or only for intermediates rather than final API release.
What suppliers support generic development of formoterol fumarate and mometasone furoate inhalers?
Generic developer patterns:
- API qualification is usually built around suppliers tied to the same regulatory filing approach (DMF referencing, impurity profile match).
- Developers may also source from intermediates to reduce lead times.
Risk points for procurement:
- Late-stage impurity drift across API vendors can trigger bioequivalence delays and formulation reformulation work.
- Inhalation performance failures often map back to powder properties that vary by plant.
What patents and regulatory filings affect supplier qualification for formoterol and mometasone APIs?
Why supplier qualification is tied to legal status:
- Even where APIs are widely available, procurement for an approved generic pathway is shaped by:
- DMF ownership and referencing
- ground rules for impurity limits tied to the approved product
- process patents that restrict certain synthesis routes in practice
Outcome:
- The effective supplier set for a given project can be smaller than the apparent market inventory.
What is the FDA Orange Book status for formoterol fumarate and mometasone furoate combinations, and how does it impact supplier selection?
High-level link between Orange Book status and sourcing:
- If the finished product has active exclusivities or unexpired patents, procurement strategies shift toward:
- licensed manufacturing pathways,
- alternative strengths,
- or delayed launches.
Procurement consequence:
- Legal exclusivity affects whether buyers pursue new filings, substitution strategies, or contract manufacturing arrangements.
How do you identify the real API suppliers behind branded inhalers and authorized generics?
Evidence sources used in supplier tracing:
- FDA submissions tied to manufacturing sites
- DMF referencing patterns
- cGMP inspection history by site
- supply chain disclosures in litigation and settlement documents
- contract manufacturing announcements for inhaler programs
Commercially relevant conclusion:
- “Who sells API” is not always the same as “who supplies the commercial finished product.”
How many API manufacturers exist for formoterol fumarate and mometasone furoate, and who are the recurring names?
Quantification required for a decision-grade answer:
- A count requires access to filing-linked and site-linked data by API strength, salt form, and route.
- Without specific product context (approved strength/device and marketed configuration), any numeric supplier count risks being incorrect.
Key Takeaways
- Supplier sets for formoterol fumarate and mometasone furoate depend on the specific marketed inhalation configuration (combination vs single ingredient, strength, and device/closure system).
- API vendors are not interchangeable at the procurement level due to spec, impurity profile, and inhalation performance requirements.
- A complete supplier roster for actionable licensing, development, or litigation use must be tied to specific FDA-approved product configurations and the associated DMF and manufacturing site footprints.
FAQs
- How do I map the API supplier for a specific formoterol fumarate and mometasone furoate inhaler sold in the US?
- What documentation is required to qualify an inhalation-grade supplier for formoterol fumarate?
- What impurity-control differences matter most between mometasone furoate API vendors?
- How does combination-product manufacturing affect API vendor qualification compared with single-ingredient products?
- Which sourcing risks typically cause delays in generic inhaler development for formoterol and mometasone?
References
No sources cited.
